Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. Journal Article

Local Library Link: Find It @ Loyola

Authors: Riedell, PA; Hamadani, M; Ahn, KW; Litovich, C; Murthy, GSG; Locke, FL; Brunstein, CG; Merryman, RW; Stiff, PJ; Pawarode, A; Nishihori, T; Kharfan-Dabaja, MA; Herrera, AF; Sauter, CS; Smith, SM
Article Title: Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma.
Abstract: BACKGROUND: While autologous hematopoietic cell transplant (autoHCT) has become a common practice for eligible patients in the front-line setting with mantle cell lymphoma (MCL), there are limited data regarding trends in autoHCT utilization and associated outcomes. METHODS: This study utilized the Center for International Blood and Marrow Transplant Research database to evaluate survival outcomes and transplant utilization in adults age = 18 years-old who underwent autoHCT within 12-months of MCL diagnosis between January 2000 and December 2018. The 19-year period from 2000-2018 was divided into 4 separate intervals, 2000-2004, 2005-2009, 2010-2014, and 2015-2018, and encompassed 5082 patients. To evaluate transplant utilization patterns, we combined MCL incidence derived from the SEER 21 database with CIBMTR reported autoHCT activity within 12-months of MCL diagnosis. Primary outcomes included overall survival (OS) along with the stem cell transplant utilization rate. RESULTS: The cumulative incidence of non-relapse mortality at 1-year decreased from 7% in the earliest cohort (2000-2004) to 2% in the latest cohort (2015-2018). Mirroring this trend, OS outcomes continually improved with time, whereby the 3-year OS was 72% in the earliest cohort and improved to 86% in the latest cohort. Additionally, we noted an increase in autoHCT utilization from 2001 to 2018, particularly in patients = 65 years old. CONCLUSIONS: This large retrospective analysis highlights utilization trends and autoHCT outcomes in patients with MCL and emphasizes the need to optimize pre- and post-transplant treatment strategies to enhance survival outcomes.
Journal Title: Transplantation and cellular therapy
Publisher: Unknown  
Date Published: 2021